Advertisement
For the successful commercialization of MammaPrint, Ferrer inCode willleverage the distribution power of its mother company Grupo FerrerInternacional, the leading Spanish pharmaceutical company in Latin America.Ferrer products are sold in 18 Latin American countries through subsidiaries,joint ventures and independent distributors. In key markets such as Brazil,Argentina, Venezuela, and Peru, Ferrer is ranked either first or second interms of distribution power.
Advertisement
"Capitalizing on Ferrer inCode's dominant position on the Iberianpeninsula, we are delighted to expand our strong partnership and makeMammaPrint available to doctors and patients in Latin America as well," saidBas van der Baan, Vice President Commercial Operation Europe/ROW of Agendia."Ferrer has a strong presence in most of the Latin American key markets, mostnotably in rapidly emerging countries such as Brazil and Argentina, and hasmade great strides towards reimbursement in a number of Latin Americancountries."
About MammaPrint(R)
MammaPrint is the first and only breast cancer recurrence test cleared bythe U.S. Food and Drug Administration (FDA). FDA clearance under the in vitrodiagnostic multivariate index assay (IVDMIA) guidelines requires clinical andanalytical validation and reporting systems to ensure patient safety issuesare addressed. Highly accurate, MammaPrint identifies patients with earlymetastasis risk - patients who are likely to develop metastases within fiveyears following surgery. Several authoritative studies have shown thatchemotherapy particularly reduces early metastasis risk. In planningtreatment, the MammaPrint test results provide doctors with a clear rationaleto assess the benefit of chemotherapy in addition to other clinicalinformation and pathology tests.
All MammaPrint tests are conducted in Agendia's CAP-accredited and CLIAcompliant service laboratories. Breast cancer recurrence assays currentlymarketed by other manufacturers have not been subject to the rigorous FDAclearance process.
About Agendia
Agendia is at the forefront of the personalized medicine revolution,striving to bring more effective, individualized treatments within reach ofpatients. Building on a cutting-edge genomics platform for tumor geneexpression profiling, the company's tests help physicians more accuratelytailor cancer treatments. Agendia markets four products, with several newgenomic tests under development. In addition, Agendia collaborates withpharmaceutical companies to develop highly effective personalized drugs inthe area of oncology. Agendia is based in Huntington Beach, California, andin Amsterdam, The Netherlands.
About Ferrer inCode
Ferrer inCode is the biotech subsidiary of Grupo Ferrer Internacional,focused on personalized medicine by providing diagnostic orientation,prognosis and prediction services based on genomics, proteomics, metabolomicsand bioinformatics platforms. The vision of Ferrer inCode is to help doctorsmake the most accurate clinical decisions for each patient through advancedbiotechnological services. Ferrer is a privately held European R&D-basedpharmaco-chemical and medical device company headquartered in Barcelona,Spain. Ferrer is the third largest Spanish pharma company in Spain, withsales and distribution in over 90 countries.
SOURCE Agendia B.V.
